Quotient Sciences 2024 ESG Report

As we reflect on 2024, Quotient Sciences has made improvements not only in accelerating drug development for our partners and patients, but also in advancing our ESG commitments.

This year marked a turning point in how we measure and manage our environmental impact. For the first time, we fully incorporated emissions from Purchased Goods & Services into our Scope 3 reporting, resulting in a more complete and transparent greenhouse gas inventory. While this led to a significant increase in reported emissions, it reflects our pledge to put accuracy over optics, a principle that underpins our entire ESG strategy. 

We also piloted the My Green Lab Ambassador Program, empowering our scientists to lead sustainability efforts from within the labs. Initiatives like these are helping us embed environmental stewardship into our day-to-day operations, from reducing energy use to rethinking single-use plastics. 

Beyond the environment, we continued to invest in our people and communities. Our global DEI training program reached colleagues across all sites, and our STEM outreach efforts inspired the next generation of scientists. We also became a proud signatory to the UN Global Compact, aligning our operations with its ten principles on human rights, labor, environment, and anti-corruption.

Throughout 2025, we are setting ambitious goals to further our ESG: committing to a Science-Based Target, expanding our My Green Lab Ambassador Program, and deepening our supplier engagement to drive sustainability across our value chain. 

Together, we are building a more sustainable, inclusive, and resilient future. Find out more about our ESG commitments.